Strides Pharma

Strides Pharma

STAR.NS
Bengaluru, India· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

STAR.NS · Stock Price

INR 1,146.80+508.35 (+79.62%)
Market Cap: $1.1B

Historical price data

Market Cap: $1.1BPipeline: 1 drugPatents: 1Founded: 1990Employees: 3000+HQ: Bengaluru, India

Overview

Strides Pharma Science Limited is a multinational pharmaceutical company with a mission to make quality healthcare accessible globally through a hybrid business model spanning regulated and emerging markets. Founded in 1990, it has evolved from a domestic Indian manufacturer into a global leader in complex generics and specialty pharmaceuticals, leveraging a vertically integrated structure with advanced manufacturing and R&D. Key achievements include a 5x increase in Q4 FY2025 net profit, a strategic 'In Africa, For Africa' initiative, and a robust portfolio of USFDA-approved facilities, positioning it for sustainable growth in the global generics market.

Infectious DiseasesOncologyAutoimmune DiseasesCentral Nervous SystemCardiovascular

Technology Platform

Integrated platform for complex generics and biosimilars, specializing in advanced formulation technologies for softgels, sterile injectables, controlled substances, and leveraging vertical integration from API to finished dosage forms.

Pipeline

1
1 drug in pipeline
DrugIndicationStageWatch
Favipiravir + NitazoxanideCovid19Phase 2

Funding History

2
Total raised:$50M
Debt$50M
IPOUndisclosed

FDA Approved Drugs

50
FLUOXETINE HYDROCHLORIDEANDASep 13, 2024
THEOPHYLLINEANDASep 5, 2024
SUCRALFATEANDAMay 21, 2024

Company Timeline

1990Founded

Founded in Bengaluru, India

2000IPO

Initial Public Offering

2021Debt

Debt: $50.0M

2024FDA Approval

FDA Approval: FLUOXETINE HYDROCHLORIDE

2024FDA Approval

FDA Approval: THEOPHYLLINE

2024FDA Approval

FDA Approval: SUCRALFATE